Draft Details
- Blood and blood components (New Edition)
- DRAFT STANDARD
- Legal Notice for Draft Standards
- Technical Committee on Blood and Blood Compone...
- Preface
- CAN/CSA-Z902:20
- 0 Introduction
- + 1 Scope
- 1.1 Management requirements for facilities coll...
- 1.2 Scope
- 1.3 Requirements for storage and use of blood p...
- 1.4 Activities within the scope of the Standard...
- 1.5 Exclusions
- 1.6 Use of shall, should, and may
- 2 Reference publications
- + 3 Definitions and abbreviations
- 3.1 Definitions
- 3.2 Abbreviations
- + 4 General
- + 4.1 Policies
- 4.1.1 Written policies for safety, quality, and...
- 4.1.2 Facility policies
- 4.1.3 Policies for process controls, quality ma...
- 4.1.4 Subsidiary facility compliance
- + 4.2 Operating procedures
- + 4.2.1 General
- 4.2.1.1 Operating procedures
- 4.2.1.2 Operating procedures review and approva...
- 4.2.1.3 Documentation of operating procedures
- 4.2.1.4 Standard operating procedures maintenan...
- 4.2.1.5 Emergency plan
- 4.2.1.6 Emergency plan
- + 4.2.2 Development, approval, and distribution o...
- 4.2.2.1 Operating procedures establishment and ...
- 4.2.2.2 Operating procedures
- 4.2.2.3 Requirements of the operating procedure...
- 4.2.2.4 Availability and revision of standard o...
- 4.2.2.5 Document control system for SOP manual
- 4.2.2.6 Document change management
- + 4.2.3 Document control
- 4.2.3.1 Quality system document control
- 4.2.3.2 Document control procedure
- 4.2.3.3 Document control
- 4.2.3.4 Superseded and obsolete operating proce...
- + 4.2.4 Storage and retention
- 4.2.4.1 Document retention
- 4.2.4.2 Retention of superseded procedures and ...
- + 4.3 Personnel
- + 4.3.1 General
- 4.3.1.1 Organizational structure and staffing r...
- 4.3.1.2 Personnel roles and responsibilities
- 4.3.1.3 Personnel qualifications
- 4.3.1.4 Personnel qualifications
- 4.3.1.5 Staffing requirements
- 4.3.1.6 Qualifications of contract and temporar...
- 4.3.1.7 Responsibility and authority
- 4.3.1.8 Qualifications of technical supervisor ...
- + 4.3.2 Training
- 4.3.2.1 Training program
- 4.3.2.2 Training program assessment
- + 4.3.3 Competency assessment and proficiency tes...
- 4.3.3.1 Competency assessment program
- 4.3.3.2 Competency assessment program evaluatio...
- 4.3.3.3 Proficiency testing program participati...
- 4.3.3.4 Proficiency test review and evaluation
- 4.3.3.5 Unsuccessful proficiency test performan...
- 4.3.4 Records
- + 4.3.5 Specific requirements for blood centres
- 4.3.5.1 Blood centre physician qualifications a...
- 4.3.5.2 Quality assurance specialist and produc...
- + 4.3.6 Specific requirements for transfusion ser...
- 4.3.6.1 Medical director qualifications and res...
- 4.3.6.2 Personnel training procedures
- 4.4 Transfusion committee
- + 4.5 Health and safety
- + 4.5.1 General
- 4.5.1.1 Health and safety procedures
- 4.5.1.2 Training and compliance monitoring syst...
- 4.5.1.3 Location, design, and construction
- 4.5.2 Biological safety
- 4.5.3 Chemical safety
- 4.5.4 Radiation safety
- + 4.6 Quality system
- + 4.6.1 General
- 4.6.1.1 Quality system
- 4.6.1.2 Responsibility for quality performance
- 4.6.1.3 Quality assurance specialist responsibi...
- 4.6.1.4 Quality system records
- 4.6.1.5 Quality manual and organizational struc...
- 4.6.1.6 Operating procedure development, valida...
- + 4.6.2 Corrective action and preventative measur...
- 4.6.2.1 Incident management
- 4.6.2.2 Corrective and preventive action proced...
- 4.6.2.3 Operational procedure changes
- 4.6.2.4 Corrective action monitoring
- 4.6.2.5 Audit of compliance
- + 4.6.3 Periodic review and audits
- 4.6.3.1 Quality system review and internal audi...
- 4.6.3.2 External audits for measuring progress ...
- + 4.6.4 Contractors, subsidiary facilities, and m...
- 4.6.4.1 Contract suppliers and testing
- 4.6.4.2 Supervision and control of subsidiary f...
- + 4.7 Process control
- 4.7.1 Validated operating procedures
- 4.7.2 Procedures for process control elements
- 4.7.3 Quality control and process control
- 4.7.4 Validation of processes for blood compone...
- 4.7.5 Blood donor screening using validated met...
- + 5 Donor selection for allogeneic blood collecti...
- + 5.1 General
- 5.1.1 Donor selection operating procedures
- 5.1.2 Donor eligibility
- 5.1.3 Donor eligibility
- 5.1.4 Donor education and information
- 5.1.5 Donor information and communication
- 5.1.6 Donor communication and deferral informat...
- 5.1.7 Donor notification to the blood centre of...
- 5.1.8 Informed consent
- 5.1.9 Donor notification of abnormal test resul...
- + 5.2 Criteria to protect the donor
- 5.2.1 General
- + 5.2.2 Age
- 5.2.2.1 Donor age requirement
- 5.2.2.2 Minor donors
- 5.2.3 Weight
- + 5.2.4 Donation interval
- 5.2.4.1 Blood donation limits
- 5.2.4.2 Collection of blood from a single donor...
- + 5.2.6 Hemoglobin and hematocrit
- 5.2.6.1 Hemoglobin concentration assessment fre...
- 5.2.6.2 Hemoglobin and hematocrit requirements ...
- 5.2.7 Current or past medical illness
- + 5.2.8 Pregnancy
- 5.2.8.1 Pregnancy deferral
- 5.2.8.2 Eligibility for maternal blood donation...
- 5.2.8.3 Deferred donation following abortion
- + 5.3 Criteria to protect the recipient
- + 5.3.1 General
- 5.3.1.1 Donor evaluation and documentation
- 5.3.1.2 Donor selection procedures temperature ...
- 5.3.1.3 Donor temperature requirements
- 5.3.1.4 Venipuncture site observation at donati...
- 5.3.1.5 Skin condition requirements
- 5.3.1.6 Donor history documentation
- 5.3.1.7 Trali implicated donor evaluation
- 5.3.1.8 Confidentiality and donor notification ...
- + 5.3.2 Personal or family history of Creutzfeldt...
- 5.3.2.1 Donor eligibility
- + 5.3.4 Receipt of blood components, human tissue...
- 5.3.4.1 Donor deferral period
- 5.3.4.2 Donor deferral for human tissue or deri...
- 5.3.5 Ingestion of medications that alter plate...
- + 5.3.6 Immunizations and vaccinations
- 5.3.6.1 Hepatitis b vaccination deferral
- 5.3.6.2 Deferral period for persons receiving l...
- 5.3.6.4 Deferral period for persons who have re...
- 5.3.7 Cancer
- + 5.3.8 Infectious diseases
- 5.3.8.1 Donor deferral criteria for hepatitis a...
- b) persons who have twice tested positive for ...
- + 5.3.9 Presence of risk factors for transmissibl...
- 5.3.9.1 Donor deferral for medical history or b...
- 5.3.9.2 Deferral criteria
- 5.3.9.3 Skin examination at venipuncture site
- 5.3.9.4 Deferral for high-risk sexual behaviour...
- 5.3.9.5 Deferral criteria for at-risk exposures...
- 5.3.9.6 Deferral period for at-risk exposure
- 5.3.9.7 Deferral for tattoo, body piercing, acu...
- + 5.3.10 Malaria
- 5.3.10.1 Donor deferral for malaria
- 5.3.10.2 Donor eligibility criteria for cellula...
- 5.3.10.3 Malaria risk travel deferral period
- 5.3.10.4 Exemption from restrictions for use of...
- 5.3.11 Other protozoan diseases
- + 6 Collection of blood components
- + 6.1 General
- 6.1.1 Operating procedures for collection of bl...
- 6.1.2 Operating procedures for blood component ...
- 6.1.3 Blood collection using closed system and ...
- 6.1.4 Donor identification and linkage
- 6.1.5 Inspection and rejection of blood bags
- + 6.2 Collection procedure
- 6.2.1 Venipuncture site preparation
- 6.2.2 Sterile glove use for palpation
- 6.2.3 Anticoagulant mixing requirement
- 6.2.4 Blood collection volume
- 6.2.5 Blood bag maximum collection limit
- 6.2.6 Bleed duration for platelet components an...
- 6.2.7 Labelling
- + 6.3 Storage and transportation from collection ...
- + 6.3.1 Storage
- 6.3.1.1 Storage of whole blood for blood compon...
- 6.3.1.2 Storage time requirements
- 6.3.2 Transportation
- 6.3.3 Blood components prepared at the collecti...
- 6.4 Therapeutic phlebotomy
- + 7 Preparation of blood components
- + 7.1 General
- 7.1.1 Operating procedures for preparation of b...
- 7.1.2 Operating procedures for storage and tran...
- 7.1.3 Sterility of equipment and solutions
- + 7.2 Open system
- 7.2.1 Sterile seal breach
- 7.2.2 Storage after sterile seal breach
- + 7.3 Sterile connecting device
- 7.3.1 Operating procedures for sterile connecti...
- 7.3.2 Sterile weld integrity testing
- 7.3.3 Sterility check verification
- + 7.4 Pre-storage leukoreduction
- 7.4.1 Red blood cells – leukocyte reduced
- 7.4.2 Red blood cells – leukocyte reduced produ...
- 7.4.3 Platelet – leukocyte reduced preparation
- + 7.5 Red blood cell components
- + 7.5.1 Red blood cells
- 7.5.1.1 Separation
- 7.5.1.2 Anticoagulant
- 7.5.1.3 Hematocit
- 7.5.1.4 Storage
- 7.5.1.5 Expiration
- + 7.5.2 Red blood cells — frozen
- 7.5.2.1 Freezing of red blood cells
- 7.5.2.2 Cryopreservation
- 7.5.2.3 Thawing and washing
- 7.5.2.4 Preparation
- 7.5.2.5 Frozen red blood cells for transfusion
- 7.5.2.6 Donor testing
- 7.5.2.7 Autologous donation status communicatio...
- 7.5.2.8 Storage of frozen red blood cells
- 7.5.2.9 Storage of thawed frozen red blood cell...
- + 7.5.3 Red blood cells — washed
- 7.5.3.1 Washing
- 7.5.3.2 Preparation
- 7.5.3.3 Leukocytes and platelets in blood compo...
- 7.5.3.4 Storage
- + 7.5.4 Red blood cells — rejuvenated
- 7.5.4.1 Rejuvenation of red blood cells
- 7.5.4.2 Storage
- 7.5.4.3 Labelling
- + 7.5.5 Red blood cells — low volume
- 7.5.5.1 Low-volume units
- 7.5.5.2 Storage
- + 7.6 Plasma components
- 7.6.1 Storage
- + 7.6.2 Fresh frozen plasma and frozen plasma
- 7.6.2.1 Fresh frozen plasma preparation
- 7.6.2.2 Frozen plasma preparation
- 7.6.2.3 Thawing and storage of plasma
- + 7.6.3 Cryoprecipitate
- 7.6.3.1 Preparation of cryoprecipitate
- 7.6.3.2 Cryoprecipitate specifications
- 7.6.3.3 Thawing of cryoprecipitate
- 7.6.3.4 Storage of thawed cryoprecipitate
- + 7.6.4 Cryosupernatant plasma
- 7.6.4.1 Thawing of plasma to prepare cryosupern...
- 7.6.4.2 Preparation
- 7.6.4.3 Storage
- 7.6.4.4 Thawing
- 7.6.4.5 Storage of thawed cryosupernatant plasm...
- + 7.7 Platelets and platelets-pheresis
- 7.7.1 Platelet specifications
- 7.7.2 Pooled pre-storage platelets specificatio...
- 7.7.3 Single donor by apheresis specifications
- 7.7.4 Platelet suspension
- 7.7.5 Storage
- + 7.8 Granulocytes
- 7.8.1 Granulocytes specifications
- 7.8.2 Storage
- 7.9 Note on placeholders
- 7.10 Note on placeholders
- + 7.11 Pooled or mixed components
- 7.11.1 Pooling
- 7.11.2 Compatibility
- 7.11.3 Storage of pooled or mixed platelet comp...
- 7.11.4 Storage of platelets pooled pre-storage ...
- + 7.12 Methods to prevent transfusion-associated ...
- 7.12.1 Irradiation or pathogen reduction
- 7.12.2 Irradiation dose requirements
- 7.12.3 Irradiation exposure verification
- 7.12.4 Dose delivery verification and documenta...
- 7.12.5 Labelling
- 7.12.6 Expiration
- 7.12.7 Labelling
- + 7.13 Quality control of allogeneic blood compon...
- 7.13.1 Evaluation of allogeneic blood component...
- 7.13.2 Volume tolerance
- + 8 Testing and labelling of blood components
- + 8.1 General
- 8.1.1 Operating procedures
- 8.1.2 Requirements
- 8.1.3 Testing
- 8.1.4 Incubation times and temperatures
- 8.1.5 Validation of in-house testing protocols
- 8.1.6 Reagents approval and control
- 8.1.7 Nonconforming results
- 8.1.8 Blood donor testing
- 8.1.9 Weak d antigen testing
- + 8.2 ABO, RhD, and other blood group antigens
- 8.2.1 ABO group determination
- 8.2.2 RhD group determination
- 8.2.3 Donor ABO and RhD group testing
- 8.2.4 Donor blood group antigen typing
- + 8.3 Tests for detecting clinically significant ...
- 8.3.1 Testing for clinically significant red ce...
- 8.3.2 Transfusion of plasma-containing blood co...
- + 8.4 Tests intended to prevent disease transmiss...
- 8.4.1 Minimum donor testing requirements
- 8.4.2 Donor testing for west nile virus (wnv)
- 8.4.3 Additional tests
- 8.4.4 Test kit approval
- 8.4.5 Use of donor screening test kits
- 8.4.6 Screening test results
- 8.4.7 Emergency release of blood components
- 8.4.8 Donor deferral for positive test results
- + 8.4.9 Syphilis deferral
- 8.4.10 Donor deferral for west nile virus
- 8.4.11 Labelling and segregation of repeat reac...
- + 8.4.12 Reintegration of repeat reactive donors
- 8.4.13 Bacterial contamination testing
- 8.5 Visual inspection
- + 8.6 Labelling
- + 8.6.1 General
- 8.6.1.1 Labelling requirements for blood bags
- 8.6.1.2 Labelling specifications
- 8.6.1.3 Blood bag labels
- 8.6.1.4 Bar coding systems
- 8.6.1.5 Review of blood component records
- 8.6.1.6 Verification
- 8.6.1.7 Labelling of modified blood components
- + 8.6.2 Blood component identification
- 8.6.2.1 Records system
- 8.6.2.2 Unit identifiers
- + 8.6.3 Labelling at collection or preparation
- 8.6.3.1 Blood bag label information
- 8.6.3.2 Blood bag label requirements
- 8.6.3.3 Collection label
- 8.6.4 Labelling prior to release into inventory...
- + 8.6.5 Special labelling requirements
- 8.6.5.1 Labelling of units with caution or cond...
- 8.6.5.2 Labeling of irradiated blood components...
- 8.6.5.3 Labeling for cmv-negative blood compone...
- 8.6.5.4 Labelling of incompletely tested blood ...
- 8.6.6 Circular of information
- + 9 Release, storage, packing, and transportation...
- + 9.1 General
- 9.1.1 Operating procedures
- 9.1.2 Traceability
- + 9.2 Release from the blood centre
- 9.2.1 Operating procedures
- 9.2.2 Release responsibility
- 9.2.3 Computer system security
- + 9.3 Release of untested blood components
- 9.3.1 Emergency release
- 9.3.2 Labelling
- 9.3.3 Release voucher requirements
- 9.3.4 Communication of completed testing
- 9.3.5 Documentation
- + 9.4 Storage
- 9.4.1 Storage temperature
- 9.4.2 Storage of equipment
- 9.4.3 Refrigerator capacity and design
- 9.4.4 Temperature monitoring and recording requ...
- 9.4.5 Alarm systems for freezers and refrigerat...
- 9.4.6 Platelet agitation
- 9.4.7 Quarantine
- 9.4.8 Segregation and security of non-released ...
- 9.4.9 Disposal of blood components
- + 9.5 Packing and transportation
- 9.5.1 General
- + 9.5.2 Facility-to-facility
- 9.5.2.1 Environmental specifications and packag...
- 9.5.2.2 Storage and transportation temperature
- 9.5.2.3 Storage and transportation temperature
- 9.5.2.4 Transportation time
- 9.5.2.5 Visual inspection and documentation pri...
- 9.5.2.6 Labelling and packaging requirements
- 9.5.2.7 Labelling of blood component containers...
- 9.5.2.8 Shipment and documentation requirements...
- 9.5.2.9 Maintaining traceability of blood compo...
- 9.5.3 Within a facility
- + 10 Orders, Requests, pre-transfusion testing, s...
- + 10.1 General
- 10.1.1 Acceptance of blood components
- 10.1.2 Operating procedures
- + 10.2 Orders to prepare blood components
- 10.2.1 Documentation of orders for blood compon...
- 10.2.2 Order requirements
- 10.2.3 Clinical indication and urgency
- 10.2.4 Issuing
- 10.2.5 Recipient identification in emergency tr...
- 10.2.6 Positive identification procedure
- + 10.3 Recipient blood samples
- 10.3.1 Identification and documentation require...
- 10.3.2 Labelling and documentation
- 10.3.3 Pre-transfusion check
- + 10.4 Testing of recipient blood
- 10.4.1 Recipient blood sample testing
- 10.4.2 Sample collection for red blood cell tra...
- 10.4.3 Reuse of original blood sample for cross...
- 10.4.4 ABO group determination
- 10.4.5 RhD group determination
- 10.4.6 Discrepancy resolution and management pr...
- 10.4.7 Screening for clinically significant red...
- 10.4.8 Comparison of current test results with ...
- + 10.5 Testing of donor blood
- 10.5.1 ABO grouping confirmation for donor red ...
- 10.5.2 Reporting of abo grouping discrepancies
- 10.5.3 Phenotyping for antigens instructions
- 10.5.4 Phenotyping of antigens other than A and...
- + 10.6 Crossmatching
- + 10.6.1 General
- 10.6.1.1 Crossmatching of red blood cells
- 10.6.1.2 Crossmatch not required
- 10.6.1.3 Blood group determination
- 10.6.2 Serological crossmatch
- + 10.6.3 Computer crossmatch
- 10.6.3.1 Computerized crossmatch system
- 10.6.3.2 Computer validation
- 10.6.3.3 Computerized crossmatch system require...
- 10.6.3.4 Serological confirmation of ABO group
- 10.6.3.5 Computerized crossmatch discrepancies
- + 10.7 Selection of blood components
- 10.7.1 ABO compatibility
- 10.7.2 Expiration date
- 10.7.3 RhD compatibility
- 10.7.4 K negative red cell
- 10.7.5 Selection of red blood cells and plasma-...
- 10.7.6 Plasma compatibility and group substitut...
- 10.7.7 ABO compatibility of cryoprecipitate com...
- 10.7.8 ABO compatibility and group substitution...
- 10.7.9 Compatibility requirements
- + 10.8 Pooled or mixed components
- 10.8.1 Pooling of platelets
- 10.8.2 Labeling requirements for pooled or mixe...
- 10.8.3 Expiration date of pooled component
- 10.8.4 Record keeping
- + 10.9 Special circumstances
- + 10.9.1 Infants under 4 months
- 10.9.1.1 Pre-transfusion testing for infants un...
- 10.9.1.2 ABO determination and compatibility te...
- 10.9.1.3 ABO compatibility confirmation for red...
- 10.9.1.4 Blood grouping for infants under four ...
- 10.9.1.5 Test method
- 10.9.1.6 Selection of red blood cell components...
- 10.9.1.7 Donor red cell crossmatching and antib...
- 10.9.1.8 Processing and donor requirements
- 10.9.1.9 Irradiated blood components storage
- 10.9.2 Massive transfusion
- + 10.9.3 Emergency transfusion
- 10.9.3.1 Release and transfusion of blood compo...
- 10.9.3.2 Recipient blood group determination
- 10.9.3.3 ABO group determination
- 10.9.3.4 Labeling of components without complet...
- 10.9.3.5 Transfusion record requirements
- 10.9.3.6 Compatibility testing and reporting
- + 10.10 Acceptability
- 10.10.1 Failed screening
- 10.10.2 Visual inspection of blood components
- 10.10.3 Documentation and record keeping
- 10.10.4 Circular of information for blood compo...
- + 10.10.5 Returning to inventory
- 10.10.5.1 Blood components return policy
- 10.10.5.2 Return to inventory criteria
- 10.10.5.3 Platelet return policy
- + 11 Transfusion of blood components
- + 11.1 Conditions of transfusion
- 11.1.1 General
- + 11.1.2 Records system
- 11.1.2.1 Records management
- 11.1.2.2 Transfusion label or tag
- 11.1.2.3 Blood transfusion record
- 11.1.2.4 Recipient medical chart update
- 11.1.2.5 Storage of red cell aliquots and pre-t...
- + 11.2 Information to recipients, including infor...
- 11.2.1 Informed consent for transfusion of bloo...
- 11.2.2 Notification of transfusion
- 11.2.3 Communication to health care professiona...
- + 11.3 Identification of recipient
- 11.3.1 Identification and verification of blood...
- 11.3.2 Identifying information discrepancy reso...
- 11.3.3 Retention of attached identification inf...
- + 11.4 Transfusion
- 11.4.1 Operating procedures for administration ...
- 11.4.2 Equipment approval
- 11.4.3 Prescription and administration
- 11.4.4 Infusion rate or duration specification
- 11.4.5 Controlled environment for blood compone...
- 11.4.6 Maximum time for red blood cell transfus...
- 11.4.7 Conditions for returning red blood cells...
- 11.4.8 Transfusion set and filter requirements
- 11.4.9 Priming of administration line and filte...
- 11.4.10 Air introduction prevention
- 11.4.11 Addition of solutions to blood componen...
- 11.4.12 Blood product preparation for administr...
- 11.4.13 Administration set change frequency
- 11.4.14 Administration sets for blood products
- 11.4.15 Recipient vital signs recording
- 11.4.16 Recipient observation and monitoring
- 11.4.17 Blood transfusion record
- + 11.5 Warming
- 11.5.1 Blood component warming during transfusi...
- 11.5.2 Blood warmers
- 11.6 Cellular blood components selected or proc...
- + 11.7 Irradiated blood components
- 11.7.1 Policy for irradiated blood components
- 11.7.2 Ensuring predetermined recipients receiv...
- 11.7.3 Release of irradiated blood components
- 11.8 Granulocytes
- + 11.9 Rh Immune Globulin (RhIG)
- 11.9.1 RhD group determination and administrati...
- 11.9.2 Administration record requirements
- 11.9.3 RhD grouping interpretation criteria
- 11.9.4 Administration of RhIG procedure require...
- 11.9.5 Postpartum administration of RhIG
- 11.9.6 Fetomaternal hemorrhage testing
- 11.9.7 Policy for RhD negative recipients recei...
- 11.10 IgA-depleted components
- + 12 Autologous blood collection and transfusion
- + 12.1 General
- 12.1.1 Operating procedures for autologous coll...
- 12.1.2 Autologous blood collection requirements...
- 12.1.3 Autologous blood collection authorizatio...
- 12.1.4 Autologous collection safety
- 12.1.5 Labelling and segregation of autologous ...
- 12.1.6 Autologous collections collection, trans...
- + 12.2 Criteria for donation
- 12.2.1 Autologous blood collection guidelines
- 12.2.2 Autologous donor selection criteria
- 12.2.3 Frequency of phlebotomy for autologous c...
- + 12.3 Testing and labelling
- + 12.3.1 Testing
- 12.3.1.1 Autologous donation group determinatio...
- 12.3.1.2 Disease agent testing
- 12.3.1.3 Disposition of blood components with p...
- 12.3.1.4 Shipping from facility to facility
- 12.3.1.5 Shipping requirements for blood compon...
- 12.3.1.6 Notification of abnormal test results ...
- + 12.3.2 Labelling
- 12.3.2.1 Labelling requirements for autologous ...
- 12.3.2.2 Labelling of untested blood components...
- + 12.4 Pre-transfusion testing and transfusion
- 12.4.1 Pre-transfusion testing requirements
- 12.4.2 Autologous blood component use prior to ...
- 12.4.3 Transfusion recipient identification
- 12.4.4 Retention of record for autologous blood...
- + 12.5 Perioperative collection
- 12.5.1 Collection and re-infusion of blood unde...
- 12.5.2 Perioperative blood collection responsib...
- 12.5.3 Quality control and quality assurance
- 12.5.4 Quality control and quality assurance pr...
- 12.5.5 Perioperative collection procedures reco...
- 12.5.6 Perioperative collection of blood from t...
- 12.5.7 Perioperative blood transfusion recipien...
- 12.5.8 Labelling requirements
- 12.5.9 Blood processing and filtering
- 12.5.10 Acute normovolemic hemodilution transfu...
- 12.5.11 Perioperative collection and transfusio...
- 12.5.12 Transfusion timeframe for shed blood
- + 13 Apheresis donation
- + 13.1 General
- 13.1.1 Operating procedures for blood component...
- 13.1.2 Operating procedures for component colle...
- 13.1.3 Donation volumes and minimum intervals
- 13.1.4 Apheresis donor eligibility
- 13.1.5 Concurrent multiple component apheresis ...
- 13.1.6 Special circumstances for shorter donati...
- 13.1.7 Medical care responsibility
- 13.1.8 Emergency medical attention
- 13.1.9 Informed consent
- 13.1.10 Documentation of red blood cell removal...
- 13.1.11 Donor deferral criteria for apheresis c...
- 13.1.12 Blood donation interval after double re...
- 13.1.13 Record keeping
- + 13.2 Collection
- 13.2.1 Apheresis collection set for single use
- 13.2.2 Solutions for apheresis procedures
- 13.2.3 Apheresis equipment safety features
- 13.2.4 Adverse event handling
- 13.2.5 Equipment fault documentation and follow...
- 13.2.6 Defect and failure investigation
- 13.2.7 Operating procedures for post-donation t...
- 13.2.8 Inspection for clots and abnormal colour...
- 13.2.9 Operating procedures for disposal of dis...
- + 13.3 Additional requirements for each type of c...
- + 13.3.1 Plasma collected by apheresis
- 13.3.1.1 Operating procedures for plasmapheresi...
- 13.3.1.2 Serum protein composition testing
- 13.3.1.3 Serum protein frequency
- 13.3.1.4 Removal of donor from program due to a...
- 13.3.1.5 Maximum quantity of plasma collection ...
- 13.3.1.6 Maximum quantity of plasma collection
- 13.3.1.7 Donation interval and limitations for ...
- 13.3.1.8 Documentation of loss of concentrated ...
- + 13.3.2 Platelets collected by apheresis
- 13.3.2.1 Plateletpheresis donation operating pr...
- 13.3.2.2 Plateletpheresis procedure approval in...
- 13.3.2.3 Plateletpheresis frequency and donor e...
- 13.3.2.4 Plasma to platelet donation interval e...
- 13.3.2.5 Donor qualification and suitability re...
- 13.3.2.6 Donors taking medications that alter p...
- + 13.3.3 Red blood cells collected by apheresis
- 13.3.3.1 Maximum volume of red blood cells remo...
- 13.3.3.2 Apheresis donation interval and total ...
- 13.3.4 Leukocytes collected by apheresis
- 13.4 Therapeutic apheresis
- + 14 Transfusion service responsibilities regardi...
- + 14.1 General
- 14.1.1 Transfusion service requirements
- 14.1.2 Operating procedures for blood products
- 14.1.3 Coordination of policies and procedures ...
- 14.2 Records
- 14.3 Requests
- + 14.4 Preparation for administration
- 14.4.1 Preparation of blood products
- 14.4.2 Training and qualification of service pe...
- 14.4.3 Preparation record
- 14.5 Administration
- + 14.6 Storage and transportation
- 14.6.1 Storage, transportation, and expiration ...
- 14.6.2 Returned blood product acceptance
- 14.6.3 Acceptance of blood products not meeting...
- 14.6.4 Policies and procedures for supplying bl...
- 14.7 Home administration
- 14.8 Adverse events
- + 15 Directed donations and designated donations
- + 15.1 Directed donations
- 15.1.1 Operating procedures for directed donati...
- 15.1.2 Directed donation program
- 15.1.3 Directed donors
- 15.1.4 Donor/recipient compatibility determinat...
- 15.1.5 Disclosure of risks for directed donatio...
- 15.1.6 Directed use only donations labeling
- 15.1.7 Directed donations and cross-over to reg...
- 15.1.8 Donations from blood relatives shall be ...
- + 15.2 Designated donations
- 15.2.1 Operating procedures for designated dona...
- 15.2.2 Designated donation program requirements...
- 15.2.3 Designated donor requirements
- 15.2.4 Designated donations and cross-over to r...
- 15.2.5 Irradiation of designated donations
- 15.2.6 Labelling requirements
- + 16 Pre-assessed donor programs
- 16.1 General
- + 16.2 Health care facility
- 16.2.1 Pre-assessed donor programs
- 16.2.2 Pre-assessed donor program policies and ...
- 16.2.3 Responsibilities of the medical director...
- 16.2.4 Documentation requirements
- 16.2.5 Pre-assessed donor blood component manag...
- 16.2.6 Donor record control
- + 16.3 Donors
- 16.3.1 Donor selection criteria
- 16.3.2 Informed consent and notification requir...
- 16.3.3 Donor counseling
- 16.3.4 Donor eligibility criteria
- 16.4 Staff
- + 16.5 Labelling
- 16.5.1 Untested for transmissible diseases
- 16.5.2 Not labelled for regular inventory
- + 16.6 Testing
- 16.6.1 Testing and infectious disease agent scr...
- 16.6.2 Blood grouping, typing, and compatibilit...
- + 17 Home transfusion
- + 17.1 General
- 17.1.1 Requirements
- 17.1.2 Operating procedures
- 17.1.3 Jurisdictional requirements
- 17.1.4 Prescription requirements
- 17.1.5 Training and qualifications of transfusi...
- + 17.2 Recipient selection
- 17.2.1 Eligibility for home transfusion
- 17.2.2 Identification of clinically significant...
- 17.2.3 Policies and procedures for home environ...
- 17.2.4 Telephone and emergency services access
- 17.2.5 Assistance during and after transfusion
- + 17.3 Informed consent
- 17.3.1 Informed consent for home transfusion
- 17.3.2 Awareness of risks associated with home ...
- 17.4 Pre-transfusion testing and selection of c...
- 17.5 Transportation
- + 17.6 Administration
- 17.6.1 Documentation of recipient's vital signs...
- 17.6.2 Immediate consultation for urgent medica...
- 17.6.3 Operating procedure for handling potenti...
- 17.6.4 Medication administration protocol
- 17.6.5 Recipient monitoring after transfusion
- 17.7 Disposal of biohazardous waste
- + 18 Adverse events
- + 18.1 General
- 18.1.1 Operating procedures for documenting, re...
- + 18.1.2 Investigation and corrective measures
- 18.1.2.1 Error and accident investigation
- 18.1.2.2 Reporting of errors and accidents in r...
- 18.1.2.3 Notification of the implicated blood c...
- + 18.2 Identifying, investigating, and reporting
- 18.2.1 Reporting of adverse transfusion reactio...
- 18.2.2 Investigation of adverse reactions
- + 18.2.3 Investigation of adverse reaction by the...
- 18.2.3.1 Notification
- 18.2.3.2 Investigation
- 18.2.3.3 Reporting
- 18.2.4 Investigation of adverse reaction by the...
- 18.2.5 Retention of reports for adverse reactio...
- + 18.3 Suspected hemolytic transfusion reactions
- 18.3.1 Management
- 18.3.2 Verification of recipient and blood comp...
- 18.3.3 Verification of blood sample
- + 18.4 Suspected bacterial sepsis
- 18.4.1 Investigation
- 18.4.2 Microbiological investigation
- 18.4.3 Blood cultures
- 18.4.4 Strain isolation and typing
- 18.4.5 Donor investigation
- 18.5 TRALI
- + 18.6 Traceback to other transfusion-transmissib...
- 18.6.1 Traceback notification
- 18.6.2 Donor deferral
- 18.6.3 Donor reinstatement
- 18.6.4 Donor investigated
- 18.6.5 Notification to blood supplier
- + 19 Removal of unsafe components and donors from...
- + 19.1 Post-donation information
- 19.1.1 Operating procedure for retrieval and di...
- 19.1.2 Notification of recipients
- 19.1.3 Documentation of post-donation informati...
- 19.1.4 Management of information received from ...
- 19.1.5 Policy for suspected TRALI cases
- 19.1.6 Donor suitability reassessment
- + 19.2 Recall of allogeneic donations found posit...
- 19.2.1 Repeat reactive allogeneic donations
- 19.2.2 Recall notification to transfusion servi...
- 19.2.3 Confirmatory results notification
- + 19.3 Lookback
- 19.3.1 Lookback for confirmed infection in bloo...
- 19.3.2 Donor lookback procedure
- 19.3.3 Notification to the transfusion services...
- 19.3.4 Notification of recipients by the blood ...
- 19.3.5 Recipient notification
- 19.3.6 Annual summary reports on lookback
- + 19.4 Recall procedure
- 19.4.1 Rapid recall of blood components
- 19.4.2 Recall operating procedure
- 19.4.3 Recall initiation
- 19.4.4 Notification of suspected errors or acci...
- 19.4.5 Recalled components
- 19.4.6 Recall communication to transfusion serv...
- 19.4.7 Recall notification
- 19.4.8 Follow-up communication
- 19.4.9 Recall final report
- + 20 Records
- + 20.1 General
- 20.1.1 Records management
- 20.1.2 Record maintenance
- 20.1.3 Record format
- 20.1.4 Electronic signature identification
- 20.1.5 Record corrections
- 20.1.6 Agreements between organizations
- 20.1.7 Record storage and access
- 20.1.8 Record development and maintenance
- 20.1.9 Retention on recording media
- 20.1.10 Data transfer responsibility
- 20.1.11 Records copying and storage
- 20.1.12 Record retention of allogeneic blood co...
- + 20.2 Blood donation
- 20.2.1 Identification and donor declaration
- 20.2.2 Recordkeeping
- 20.2.3 Manufacturer and lot number
- 20.2.4 Record of problems
- 20.2.5 Donation number reconciliation
- 20.2.6 Records for indefinitely deferred donors...
- + 20.3 Blood component preparation
- 20.3.1 Donation history
- 20.3.2 Records of blood component preparation m...
- 20.3.3 Retention of manufacturer information
- 20.3.4 Retention of records
- + 20.4 Final product
- 20.4.1 Blood component label
- 20.4.2 Records and documentation
- + 20.5 Distribution
- 20.5.1 Traceability
- 20.5.2 Identification of non-conforming blood c...
- 20.5.3 Retention of distribution records
- + 20.6 Storage, retention, and archiving
- 20.6.1 General
- + 20.6.2 Records of donors and donor blood compon...
- 20.6.2.1 Information for allogeneic donations
- 20.6.2.2 Retention of donor suitability assessm...
- 20.6.2.3 Retention of autologous donation infor...
- 20.6.2.4 Retention of collection record for aut...
- 20.6.2.5 Retention of records
- 20.6.2.6 Retention of investigations and report...
- 20.6.2.7 Retention of records for determination...
- 20.6.2.8 Retention of post-donation information...
- + 20.6.3 Records of recipients
- 20.6.3.1 Retention of recipient records
- 20.6.3.2 Retention of transfusion records
- 20.6.3.3 Retention of investigation and reports...
- 20.6.3.4 Retention of adverse event records
- 20.6.3.5 Retention of blood sample collection r...
- + 20.6.4 Other retention records
- 20.6.4.1 Lookback and traceback documents
- 20.6.4.2 Personnel qualifications and training ...
- 20.6.4.3 Quality control records
- 20.6.4.4 Product complaint records retention
- 20.6.4.5 Quality assurance reports and internal...
- 20.6.4.6 Records for importation of blood compo...
- 20.6.4.7 Packing/shipping documents
- + 20.7 Product complaints, recalls, and correctiv...
- 20.7.1 Retention of distribution records
- 20.7.2 Retention of corrective action for blood...
- + 21 Computer systems
- 21.1 General
- + 21.2 Computer system description and documentat...
- 21.2.1 System documentation
- 21.2.2 Documentation of application program dev...
- 21.2.3 Operating procedures for computer system...
- + 21.3 Computer system validation and periodic te...
- 21.3.1 Validation and documentation
- 21.3.2 Maintenance and testing
- + 21.4 Change control
- 21.4.1 Change control for computer system
- 21.4.2 System re-validation
- + 21.5 Staff qualification
- 21.5.1 Competency requirements for computer sys...
- 21.5.2 Personnel training and competency
- + 21.6 Records
- 21.6.1 Documentation requirements
- 21.6.2 Electronic records backup and maintenanc...
- 21.6.3 Printing
- 21.6.4 Data quality assurance
- 21.6.5 Data access
- 21.6.6 Operating procedure and error correction...
- 21.6.7 Alternate system for continuous operatio...
- 21.6.8 Operating procedures for confidentiality...
- + 22 Buildings and facilities
- + 22.1 General
- 22.1.1 Location, design, construction, and adap...
- 22.1.2 Facility security
- 22.1.3 Hand hygiene facilities location and sup...
- 22.1.4 Faucet operation and hand drying
- 22.1.5 Personnel hygiene
- 22.1.6 Safety equipment and facilities availabi...
- 22.1.7 Emergency power source for critical equi...
- 22.1.8 Pest control program
- + 22.2 Blood component processing and testing are...
- 22.2.1 Access for cleaning
- 22.2.2 Surfaces and materials
- 22.2.3 Blood component processing area separati...
- + 22.3 Sanitation program
- 22.3.1 Sanitation program
- 22.3.2 Cleaning procedures
- 22.3.3 Documentation for storage and use of dis...
- 22.3.4 Collection and disposal of biological an...
- + 22.4 Mobile sites
- 22.4.1 Mobile clinic site selection considerati...
- 22.4.2 Donor privacy
- 22.5 Receipt and storage of incoming goods, sup...
- + 23 Mechanical equipment
- + 23.1 General
- 23.1.1 Evaluation and maintenance
- 23.1.2 Requirements
- 23.1.3 Equipment for blood collection, testing,...
- + 23.2 New equipment
- 23.2.1 Installation, qualification, and validat...
- 23.2.2 Requirements
- + 23.3 Calibration and validation
- 23.3.1 Calibration procedure
- 23.3.2 Calibration labeling
- 23.3.3 Calibration schedule and documentation
- 23.3.4 Records retention
- + 23.4 Equipment maintenance
- 23.4.1 Maintenance and service
- 23.4.2 Records
- 23.4.3 Cleaning and decontamination
- + 23.5 Repairs
- 23.5.1 Malfunction procedures
- 23.5.2 Maintenance and calibration
- Annex A (informative)
- Annex B (informative)
1.1 Management requirements for facilities collecting, processing, storing, and using human blood components for transfusion
This Standard provides management requirements for facilities that collect, process, store, and use human blood components for transfusion. It addresses issues of safety, efficacy, and quality for recipients, safety of donors, management of blood components, and safety of facility personnel and others who are exposed to or potentially affected by blood components.
1.2 Scope
This Standard applies to blood centres, transfusion services, and to any other organization that collects, processes, stores, or uses human blood components for transfusion.
1.3 Requirements for storage and use of blood products
It also includes requirements for the storage and use of blood products, when such products are within the responsibility of an organization that is covered by this Standard.
Note: While this Standard does not specifically apply to organizations that manage blood products but not blood components (e.g., a hospital pharmacy), these organizations are encouraged to review the relevant requirements for blood products and incorporate them as appropriate into their procedures.
1.4 Activities within the scope of the Standard
As a management standard, this Standard is not intended to replace detailed specifications and operating procedures; rather, it is intended for use in their preparation. It includes requirements for policies and procedures, quality management, personnel, physical plant, and equipment. In addition, this Standard outlines specific requirements to be included in the facility’s operating procedures for the following activities:
a) donor selection for allogeneic blood collection;
b) collection of blood components for transfusion;
c) preparation of blood components;
d) testing and labelling of blood components;
e) release, storage, packing, and transportation;
f) requests, pre-transfusion testing, selection of components, and acceptance criteria;
g) transfusion;
h) autologous blood collection and transfusion;
i) apheresis donation;
j) transfusion service responsibilities regarding blood products used in the facility;
Note: This Item refers to blood products that are managed directly through the transfusion service, as opposed to those managed by other services, e.g., the pharmacy.
k) directed donations and designated donations;
l) pre-assessed donor programs;
m) home transfusion;
n) adverse event monitoring and corrective action;
o) removal of unsafe components and donors from the blood supply;
p) record management; and
q) validation and maintenance of computer systems.
1.5 Exclusions
This Standard does not include requirements for activities associated with
a) the collection of plasma for use in the manufacture of plasma products; and
b) the processing, manufacture, or commercial distribution of blood products, including solvent detergent plasma.
Note: Plasma for use in the manufacture of a drug for human use is covered under the Blood Regulations.
1.6 Use of shall, should, and may
In this Standard, “shall” is used to express a requirement, i.e., a provision that the user is obliged to satisfy in order to comply with the standard; “should” is used to express a recommendation or that which is advised but not required; and “may” is used to express an option or that which is permissible within the limits of the Standard.
Notes accompanying clauses do not include requirements or alternative requirements; the purpose of a note accompanying a clause is to separate from the text explanatory or informative material.
Notes to tables and figures are considered part of the table or figure and may be written as requirements.
Annexes are designated normative (mandatory) or informative (non-mandatory) to define their application.
You may comment on any section of this document by clicking the “Submit Comment” link at the bottom of the relevant section.